Latest News

Category: News

See all

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

Clinical, News,

Telix today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix,...

Read more

OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

Clinical, News,

Telix today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal...

Read more

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

Clinical, News,

Telix today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The American College of Nuclear Medicine (ACNM)...

Read more

Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain

Clinical, News,

Telix today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for treating pain associated with bone...

Read more

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

ASX, News,

Telix today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated...

Read more

TLX400 Therapy Published in Journal of Nuclear Medicine

Clinical, News,

Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in the Journal of Nuclear Medicine. TLX400 demonstrated clinical antitumor activity with a manageable safety...

Read more

Telix Announces Record-Breaking Presence at EANM 2025

ASX, News,

Telix today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Barcelona...

Read more

CMS Grants Transitional Pass-Through Status for Gozellix

ASX, News,

Telix today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide...

Read more

IMRA Surgical Announces Collaboration with Telix Pharmaceuticals to Advance Radio-Guided Surgery Education and Training

News,

IMRA and Telix announce a collaboration to accelerate the development of advanced training models and enhance the integration of cutting-edge radio-guided surgical...

Read more

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Clinical, News,

Telix today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68...

Read more